News & Updates

Show Multimedia Only

Vunakizumab beneficial in axial spondyloarthritis

16 May 2026

Treatment with vunakizumab appears to yield substantial improvements in signs and symptoms of radiographic axial spondyloarthritis (r-axSpA), as shown in a phase 2/3 trial.

Vunakizumab beneficial in axial spondyloarthritis

16 May 2026

Daratumumab shows promise in immune thrombocytopenia

15 May 2026

Treatment with daratumumab yields rapid and durable therapeutic effects and shows acceptable safety profile in adults with immune thrombocytopenia, according to a phase 2 trial.

Daratumumab shows promise in immune thrombocytopenia

15 May 2026

Linaclotide improves bowel movements, abdominal symptoms in adults with severe CIC

15 May 2026 by

Treatment with either dose of linaclotide (72 or 145 µg) showed improves bowel movement frequency and abdominal symptoms in adults with severe chronic idiopathic constipation (CIC), according to a post hoc pooled analysis of phase III studies presented at DDW 2026.

Linaclotide improves bowel movements, abdominal symptoms in adults with severe CIC

15 May 2026

Semaglutide may be beneficial to individuals with alcohol use disorder, obesity

14 May 2026

In treatment-seeking individuals with alcohol use disorder and obesity, semaglutide appears to help reduce alcohol consumption, as shown in a study.

Semaglutide may be beneficial to individuals with alcohol use disorder, obesity

14 May 2026

Investigational calcium channel modulator alleviates central neuropathic pain

13 May 2026 by

The novel third-generation calcium channel modulator crisugabalin appears to be safe and efficacious in the treatment of central neuropathic pain, as shown in a phase 3 trial.

Investigational calcium channel modulator alleviates central neuropathic pain

13 May 2026

Levacetylleucine eases symptoms in patients with ataxia-telangiectasia

13 May 2026 by

Treatment with levacetylleucine significantly improves ataxia symptoms in paediatric and adult patients with ataxia-telangiectasia (A-T) compared with placebo, according to the phase III IB1001-303 trial presented at AAN 2026.

Levacetylleucine eases symptoms in patients with ataxia-telangiectasia

13 May 2026

Novel cellular therapy delays upper limb decline in DMD

12 May 2026 by

The investigational allogeneic cell therapy deramiocel helps mitigate the progression of upper limb disease in young patients with Duchenne muscular dystrophy (DMD), as shown in the pivotal phase 3 HOPE-3 study.

Novel cellular therapy delays upper limb decline in DMD

12 May 2026

First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC

12 May 2026 by

Combination treatment with capivasertib and paclitaxel falls short of prolonging overall survival (OS) compared with placebo plus paclitaxel in patients with metastatic triple-negative breast cancer (TNBC), either in the overall or PIK3CA/AKT1/PTEN-altered populations, as shown in the CAPItello-290 trial

First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC

12 May 2026

Auranofin-sirolimus combo delivers no antineoplastic activity in recurrent ovarian cancer

12 May 2026

Inhibition of the protein kinase C iota (PKCι) with auranofin and sirolimus does not provide antineoplastic effects in patients with recurrent high-grade serous ovarian cancer, reports a phase II study.

Auranofin-sirolimus combo delivers no antineoplastic activity in recurrent ovarian cancer

12 May 2026

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

12 May 2026 by

Perioperative adebrelimab plus chemotherapy improves event-free survival (EFS) and major pathological response (MPR) in individuals with resectable stage II/III non-small cell lung cancer (NSCLC) in an interim analysis.

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

12 May 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Vunakizumab beneficial in axial spondyloarthritis

Vunakizumab beneficial in axial spondyloarthritis

Daratumumab shows promise in immune thrombocytopenia

Daratumumab shows promise in immune thrombocytopenia

Linaclotide improves bowel movements, abdominal symptoms in adults with severe CIC

Linaclotide improves bowel movements, abdominal symptoms in adults with severe CIC

Semaglutide may be beneficial to individuals with alcohol use disorder, obesity

Semaglutide may be beneficial to individuals with alcohol use disorder, obesity

Investigational calcium channel modulator alleviates central neuropathic pain

Investigational calcium channel modulator alleviates central neuropathic pain

Levacetylleucine eases symptoms in patients with ataxia-telangiectasia

Levacetylleucine eases symptoms in patients with ataxia-telangiectasia

Novel cellular therapy delays upper limb decline in DMD

Novel cellular therapy delays upper limb decline in DMD

First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC

First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC

Auranofin-sirolimus combo delivers no antineoplastic activity in recurrent ovarian cancer

Auranofin-sirolimus combo delivers no antineoplastic activity in recurrent ovarian cancer

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?